New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.96 2.22 +1.67%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. (MRK) Earnings & Analysis

Updated · Covers results through Q3 FY2026 · Earnings call · Latest filing 10-Q filed Nov 4, 2026 · How this is made

Latest quarter

Merck reported third-quarter revenue of $18.1 billion, above the $17.2 billion consensus, and adjusted earnings of $2.49 per share, above the $2.12 consensus. Revenue rose from $17.3 billion a year earlier, while diluted earnings per share fell to $2.04 from $2.32.

The filing attributed sales growth to oncology, cardiometabolic and specialty products, and animal health, partly offset by a decline in vaccines and infectious diseases. Combined Keytruda and Keytruda Qlex sales grew 6%, with the filing citing higher U.S. pricing and demand. Gardasil sales benefited from U.S. public-sector purchasing and higher net pricing, while generic competition reduced sales of Januvia and Janumet.

Merck’s gross margin fell to 72.9% from 77.7%; the filing cited higher intangible-asset amortization, restructuring costs, acquisition-related inventory adjustments and production costs. Operating margin fell to 31.9% from 37.9%. In the preceding quarter, Merck generated $4.5 billion in free cash flow, compared with $2.5 billion in Q2 FY2025.

Q3 FY2026 Q3 FY2025 Change
Revenue $18.1 billion $17.3 billion 4.68%
Diluted EPS $2.04 $2.32 −11.9%
Gross margin 72.9% 77.7% −4.7 percentage points
Operating margin 31.9% 37.9% −6.0 percentage points
Free cash flow $4.5 billion $2.5 billion 77.0%
Against the consensus Reported Consensus Result
Adjusted EPS $2.49 $2.12 Beat by 17.5%
Revenue $18.1 billion $17.2 billion Beat by 4.94%

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

CFO Caroline Litchfield said Keytruda family growth reflected uptake in earlier-stage cancers and continued demand in metastatic disease. Keytruda Qlex, the injectable version, had $830 million in quarterly sales. Asked about adoption, oncology president Yanni Oosthuizen reiterated the objective of 30% to 40% U.S. adoption by the end of 2027. He said Merck would not supply the product in several European countries while it works to overturn a Dutch court decision.

Litchfield said favorable U.S. purchase timing contributed approximately $550 million to third-quarter sales. In response to a question, she said the Keytruda and Winrevair portions should unwind in the fourth quarter; most of the vaccine benefit, predominantly Gardasil, should unwind in 2027.

On LipFendra, specialty business president Brian Ford said the quarter brought more than 11,000 prescriptions from over 6,500 prescribers. He said sampling and coupon programs would affect near-term revenue while Merck negotiates access with payers. CEO Rob Davis said the company was not giving specifics on its revenue forecasts for the product at that moment.

Litchfield said quarterly non-GAAP gross margin decreased to 81.4%, while operating expenses rose as Merck invested in launches and its pipeline. Asked about 2027, she described it as another investment year and said new products and animal health would be partly offset by more than $2 billion in headwinds from generic competition and losses of exclusivity. She also expected Keytruda growth to moderate as several indications reach peak penetration, with pricing pressure outside the U.S. and policy dynamics in Germany under review.

Davis said clinical data had increased his confidence in Merck’s longer-term revenue opportunity and that the company expected to raise its earlier $70 billion figure.

Guidance

Merck narrowed its FY2026 revenue outlook to $66.8 billion–$67.3 billion from $66.3 billion–$67.3 billion. It raised its non-GAAP EPS range to $2.77–$2.82 from $2.66–$2.76.

Merck now expects non-GAAP operating expenses of $42.4 billion–$42.9 billion, compared with $42.0 billion–$42.7 billion previously. Its expected non-GAAP tax rate is 32% to 33%, down from 35% to 36%.

Metric For Guide Previous guide Change
Market share, Keytruda Qlex US FY2027 30.0%–40.0% — New
Operating expenses, Underlying FY2027 Merck expects underlying operating expenses to increase at a mid to high single-digit rate in FY2027. — —
Gross margin FY2027 Merck expects its gross margin to increase in FY2027. — —
Revenue, Keytruda FY2027 Merck expects Keytruda revenue growth to moderate in FY2027. — —
Revenue FY2027 Merck expects modest revenue growth in FY2027. — —
Share repurchases FY2026 $3.0 billion — New
EPS, non-GAAP FY2026 $2.77–$2.82 — New
Tax rate, non-GAAP FY2026 32.0%–33.0% 35.0%–36.0% Cut
Operating expenses, non-GAAP FY2026 $42.4 billion–$42.9 billion — New
Gross margin, non-GAAP FY2026 81.0% — New
Revenue FY2026 $66.8 billion–$67.3 billion $66.3 billion–$67.3 billion Held
EPS, non-GAAP FY2026 $2.66–$2.76 — —
Operating expenses, Other Expense FY2026 $1.4 billion — New
Tax rate FY2026 35.0%–36.0% — New
Gross margin FY2026 81.0% — New
EPS FY2026 $2.66–$2.76 — New